Acting FDA commissioner Janet Woodcock explains how government, researchers, doctors and patients can contribute to improving the clinical research system.
With the Engagement Solution Center, the patient-recruitment services specialist is aiming to improve the patient-centricity and inclusivity of studies.
According to a leader from the pharma firm, considering a patient’s needs and seeing them as a whole person is vital to successful studies and drug design.
The owner of the pharmacy giant has announced plans to partner with various stakeholders in an effort to effect improvements across the trial ecosystem.
A representative from the digital experience management firm discusses how improving the quality of tech interactions with patients can elevate results.
The two tech-focused firms are joining forces to work on technology solutions aimed at improving patient recruitment and enrollment for various studies.
A leader from the clinical trial technology firm suggests ways to design research from the start to help accelerate studies and avoid stumbling blocks.
According to a leader from Saama Technologies, keeping competitive in the face of technology evolution requires staff that can keep up with the changes.
This month’s roundup of new equipment, technology partnerships, and other news includes items from Ajinomoto, Elligo, Syneos, ACD/Labs and other companies.
In this third part of a series on the state of clinical research, the acting FDA commissioner talks about possible pathways to improving the infrastructure.
The company reportedly will utilize the investment funding to expand its research platform, and to advance six of its preclinical therapeutic programs.
The UK-based development and research firm hopes to accelerate patient access to psychedelic therapies for treatment of various mental health conditions.
A leader from clinical-stage pharma firm NuCana shares promising results for its ProTides therapies and hopes the drugs can elevate outcomes for patients.
Interim data reportedly indicates Noxopharm’s Veyonda could be effective in treating cytokine storm, an inflammatory effect associated with moderate cases.
A leader from oncology trial insights and analysis specialist Inteliquet discusses how cancer studies can recover after the impact of the global pandemic.
The trial technology provider and contract research organization will collaborate on tech and process solutions designed to accelerate clinical studies.
In this second part of a series on the state of clinical research, a leader from Javara lays out ideas to bring clinical research and care closer together.
The newly formed company (valued at $1.05b USD) will center on funding the firm’s decentralized trial technology platform and exploring new opportunities,
This month’s roundup of new hires, investment funding, partnerships, and other industry news includes key firms such as Clinical Ink, Medable, CPhI, and Sterling Pharma.
In the face of increasing demand for decentralized clinical trials and remote technology, the company has received funding to enable its further expansion.
A leader from the clinical development services provider recommends using industry modal values to avoid protocol amendments, enrollment problems and more.
In this first part of a series on the state of clinical research, an expert shares insightful ideas on how to improve patient experience and study results.
A leader from the CRO talks about increased use of electronic patient-reported outcomes in research, challenges of adoption, and how ePRO benefits trials.
The two companies plan to collaboratively explore ways to combine 3D printing and nanotechnology, in order to create nanoparticle-enabled dosage forms.
Published by Tabula Rasa Healthcare, the report looks at the MedWise Risk Score, technology designed to determine ADE risk rising from medication regimens.
The 6th annual Clinical Research as a Care Option conference, taking place April 26-27, brings together experts seeking solutions to elevate the industry.
An advanced cancer detection platform from C2i Genomics (reportedly capable of spotting miniscule traces of the disease) recently landed $100m in funding.
Leaders from AmerisourceBergen's World Courier and Lash Group tell how bringing trial supplies and services to patients can boost recruitment and retention.
A leader from the laboratory solutions provider talks about how the virus has created challenges for researchers, and how those obstacles might be cleared.
ImmunoScape plans to use the investor funds to grow its Asia presence, expand into the US, and to further develop its Deep Immunomics platform technology.
The two technology companies plan to work together to provide a unified platform that serves to streamline workflow, RWE generation and data harmonization.
A leader from digital health solutions firm CitiusTech suggests use of fast healthcare interoperability resources is useful in the face of evolving tech.
One Health’s FidoCure is using genomics and AI technology to develop precision oncological treatments, and the work is benefiting human cancer research.
The Institute for Clinical and Economic Review will use Aetion observational real-world evidence to evaluate potential drugs from Takeda and CSL Behring.
The two companies have partnered to develop a systemic erythematosus assessment review to streamline clinical trials centered on the autoimmune disease.
The collaboration centers on development of precision cancer treatments, through discovery and validation of next-generation DNA damage response targets.
Leaders from the supply chain solutions company share their thoughts on challenges associated with virtual and hybrid trials, and the COVID-19 pandemic.
New research findings suggest that an immunotherapy assay enables determination of PD-L1 status in a high percentage of cancer patients and could guide personalized treatment selection.
The AWARE for All virtual event series aims to educate and engage the public as important partners in clinical trials and development of new treatments.
A leader from the global CRO discusses how putting the patient first in clinical research is essential to discovering new therapies for orphan diseases.
Especially with the COVID-19 pandemic impacting studies, the company says, putting patients at the center of studies and trial tech must be top priority.
